Ozempic now available in India
GS3Economy · S&T · Environment · Security· Biotechnology & health research· Prelims·
Why in news
Novo Nordisk has launched Ozempic, a GLP-1 receptor agonist, in India for the treatment of type 2 diabetes.
Background
Ozempic is a once-weekly injection available in 0.25 mg, 0.5 mg, and 1 mg doses via FlexTouch Pen. It is approved as a first-line treatment for adults with type 2 diabetes alongside diet and exercise.
Facts for Prelims
- S&TOzempic is a GLP-1 receptor agonist (RA) used for type 2 diabetes.
- BodyThe World Health Organization (WHO) included semaglutide on its Model List of Essential Medicines.
- FactOzempic is administered as a once-weekly injection in doses of 0.25 mg, 0.5 mg, and 1 mg.
For Mains
Q. Discuss the significance of GLP-1 receptor agonists in managing chronic metabolic disorders and the implications of WHO's Model List of Essential Medicines on global healthcare accessibility.
Dimensions to cover in your answer
- Public health equity: Balancing the high cost of branded GLP-1 RAs with the need for affordable diabetes management
- Regulatory oversight: Ensuring safety and efficacy standards for injectable medications in the Indian pharmaceutical market
Keywords: GLP-1 receptor agonist · Type 2 Diabetes · Model List of Essential Medicines · Metabolic health · Pharmacology
More Science & Technology notes
- Could rewiring macrophage metabolism make TB treatments shorter? · 19 December 2025
- With freebies, OpenAI, Google vie for Indian users and training data · 18 December 2025
- H5N1: Indian scientists predict how bird flu could spread to humans · 18 December 2025
- Lok Sabha clears SHANTI Bill amid questions over liability clause · 17 December 2025
- Kavach installed on 2,000 km of rail network; rollout moving very fast, Vaishnaw tells Lok Sabha · 17 December 2025
- PM E-DRIVE scheme: after passenger vehicles, Kerala eyeing freight electrification · 17 December 2025
Something wrong, or something missing?
Spotted a mistake in a note, or want a topic, format or PDF that would help your preparation? Write to us. We read every mail and fix errors fast.
This note is generated automatically from SatyaDheesh's news feed and mapped to the UPSC CSE syllabus. Check facts against the original report or PIB before using them in an answer.